Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer

 Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer

Shots:

  • The P-III KEYNOTE-826 trial evaluates Merck’s Keytruda (200mg, IV, q3w for up to 35 cycles) + Pt-based CT vs PBO + CT with/out bevacizumab in 617 patients aged b/w 22- 82yrs. with persistent, recurrent, or metastatic cervical cancer
  • The results showed a 33% reduction in the risk of death; m-OS (24.4 vs 16.5mos.), m-PFS (10.4 & 8.2 mos.); ORR (65.9% & 50.8%); m-DoR (18.0 & 10.4mos.), TRAEs grade ≥3 (68.4% & 64.1%), discontinuation of the treatment due to TRAEs (31.3% & 3.3%) in patients with combination therapy. The results were consistent with/out bevacizumab use
  • Keytruda is an anti- PD-1 therapy that increases the ability of the body’s immune system to help detect and fight tumor cells

Click here to­ read full press release/ article | Ref: Merck | Image: The Conversation

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post